Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

Adaptive Design in Clinical Trials: When and How to Apply

Learn how adaptive design can reduce the cost and length of drug development and improve the probability of success.

Faculty

Weidong  Zhang, PhD

Weidong Zhang, PhD

Vice President, Head of Biometrics , Sana Biotechnology, United States

Dr. Weidong Zhang is currently the Vice President, Biostatistics and Programming at Jounce Therapeutics. He oversees biostatistics and programming to support end-to-end clinical development in immuno-oncology regarding study design, execution and medical affairs. Prior to Jounce, he was a Senior Director Biostatistics at Pfizer focusing on clinical development in inflammation & immunology and oncology. Dr. Zhang has 20 years of experience in all phases of clinical development including Phase 1/PoM, Early Signal of Efficacy (ESoE), Phase 2a/b, Phase 3 and low-interventional studies. He has extensive knowledge in biomarker enrichment design and adaptive design.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.